Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc. (Nasdaq: SEER) is a life sciences company focused on deep, unbiased proteomics, and the SEER news feed reflects that focus. Company press releases highlight how Seer’s Proteograph Product Suite—combining proprietary engineered nanoparticles, automation instrumentation, consumables, and analytical software—is being used in large-scale and translational research across cardiovascular disease, oncology, aging biology, and other areas of human health.
Investors and researchers following SEER news will find regular updates on financial results, platform launches, and scientific validation. Seer’s quarterly earnings announcements describe revenue from Proteograph instruments, consumable kits, and Technology Access Center service projects, along with commentary on adoption of its platform and the growth of third-party publications and preprints that use its technology.
The news stream also covers Seer’s presence at major scientific and investor conferences. Releases detail presentations at meetings such as the Human Proteome Organization World Congress and the American Society of Human Genetics, where independent and collaborative studies showcase applications of the Proteograph platform in deep plasma proteomics, biomarker discovery, proteogenomics, and multi-omic precision medicine research. Other items include participation in healthcare and life sciences investor conferences, as well as board and governance updates.
For those tracking how proteomics technologies are being deployed in population-scale and translational studies, Seer’s news provides insight into collaborations, such as population-scale proteomics projects and genome-wide association studies using the Proteograph platform. Bookmarking the SEER news page offers a centralized view of Seer’s financial disclosures, scientific milestones, and corporate developments as reported in its official communications.
Seer (Nasdaq: SEER) announced its Board unanimously rejected a revised unsolicited proposal from the Radoff-JEC Group received April 24, 2026, offering $2.35 per share in cash plus a contingent value right. The Board concluded the proposal materially undervalues Seer versus cash, investments and platform value.
The Board highlighted Seer’s Proteograph product suite, selection for Singapore’s SGK100 study, more than 80 peer‑reviewed publications, and 240 patents and applications (82 issued), and said stockholders need take no action at this time.
Summary not available.
Seer (Nasdaq: SEER) confirmed receipt of a non-binding, unsolicited proposal from the Radoff-JEC Group to acquire all Class A shares for $2.25 per share in cash plus a contingent value right.
The group also nominated three director candidates for Seer’s 2026 Annual Meeting. The Board, with financial and legal advisors, will review the Proposal and nominations; no stockholder action is required at this time.
Summary not available.
Seer (Nasdaq: SEER) will provide its Proteograph product suite to deeply profile the plasma proteome in 10,000 PRECISE-SG100K participant samples, integrated with Thermo Fisher Olink Reveal and Orbitrap Astral data.
The collaboration aims to add deep, unbiased proteomics to a ~100,000-person, multi-ancestry Singapore cohort to support biomarker discovery, drug target biology, and population-level risk models.
Seer (Nasdaq: SEER) said the U.S. Patent and Trademark Office Patent Trial and Appeal Board issued a Final Written Decision on March 23, 2026 upholding 23 claims of U.S. Patent No. 11,435,360, which protect its Proteograph nanoparticle protein enrichment methods.
The ’360 patent is owned by Brigham and Women’s Hospital and exclusively licensed to Seer; the decision affirms key claim coverage of Proteograph’s nano- and microparticle protein-corona technology.
Seer noted the platform is supported by an IP portfolio of more than 240 issued and pending patents, including 80 issued patents.
Summary not available.
Seer (Nasdaq: SEER) adopted a limited-duration tax benefit preservation plan to protect approximately $262 million of net operating loss carryforwards as of December 31, 2025. The plan seeks to limit ownership accumulation above 4.9% of Class A stock without Board approval.
The Board declared a dividend of one transferable right per outstanding Class A share, with a record date of March 9, 2026. The NOL Plan expires February 25, 2029, or earlier on February 25, 2027 if shareholders do not ratify it at Seer’s 2026 annual meeting.
Seer (Nasdaq: SEER) reported fourth-quarter and full-year 2025 results, with $4.2M revenue in Q4 and $16.6M for full year 2025. Installed base grew to 82 instruments (67% YoY) and year-end cash, cash equivalents and investments were approximately $240.6M.
Gross margin was ~51% for 2025, operating expenses fell to $86.5M, and net loss narrowed to $73.6M. Seer expects 2026 revenue of $16M–$18M (midpoint ~3% growth).
Radoff-JEC Group (owners of ~7.5% of SEER) sent an open letter to Seer (NASDAQ: SEER) on February 23, 2026, pressing for immediate governance and operational change.
The letter cites a >96% share price decline since Seer’s 2020 IPO, 2025 revenue midpoint of $17.5M, cumulative cash used in operations of $138.8M and capex of $11.4M (total cash use $150.2M), a market cap of $110.5M vs. $251.2M net cash, and CEO Omid Farokhzad’s reported total compensation of $24.9M (2021–2024).